Secondary Hyperparathyroidism: Pathophysiology and Treatment

References

1. ↵
   Poggio ED, Rule AD. A critical evaluation of chronic kidney disease-should isolated reduced estimated glomerular filtration rate be considered a ‘disease’? Nephrol Dial Transplant 2009; 24: 698–700.

   OpenUrlFREE Full Text
2. ↵
   Coresh J, Selvin E, Stevens L, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–47.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009; 44: 666–70.

   OpenUrlPubMed
4. ↵
   Biber J, Custer M, Magagnin S, et al. Renal Na/Pi-cotransporters. Kidney Int 1996; 49: 981.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997; 20: 303–9.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534–40.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Holick MF. Vitamin D and the kidney. Kidney Int 1987; 32: 912–29.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Nabeshima Y. Clinical discovery of alpha-Klotho and FGF-23 unveiled new insight into calcium and phosphate homeostasis. Calcium 2008; 18: 923–34.

   OpenUrl
9. ↵
   Kovesdy CP, Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 2008; 40: 427–40.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D. PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–8.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519–30.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345–54.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–201.

    OpenUrlPubMed
15. ↵
    Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003; 16: 186–8.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006; 48: 37–49.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388–96.

    OpenUrlAbstract/FREE Full Text
18. ↵
    Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3: 96–102.

    OpenUrlAbstract
19. ↵
    Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245–52.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130–7.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Tonelli M, Wiebe N, Culleton B, et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856–66.

    OpenUrlAbstract/FREE Full Text
22. ↵
    Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68: 386–91.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Finn WF, SPD 405–307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191–202.

    OpenUrlCrossRefPubMedWeb of Science
24. ↵
    Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 178–85.

    OpenUrlAbstract/FREE Full Text
25. ↵
    Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840–53.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F. ‘Pulse oral’ versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 1997; 77: 267–72.

    OpenUrlPubMedWeb of Science
27. ↵
    Cuppari L, Garcia-Lopes MG. Hypovitaminosis d in chronic kidney disease patients: prevalence and treatment. J Ren Nutr 2009; 19: 38–43.

    OpenUrlPubMed
28. ↵
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446–56.

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 2005; 67: 760–71.

    OpenUrlCrossRefPubMedWeb of Science
30. ↵
    Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 1997; 82: 85–6.

    OpenUrlPubMed